Bayer buys Merck OTC portfolio

Share this article:
Bayer buys Merck OTC portfolio
Bayer buys Merck OTC portfolio

Merck is free of its over-the-counter business. After being snubbed first by Novartis, and most recently by Reckitt Benckiser, the Whitehouse, NJ, drugmaker announced Tuesday that Bayer has agreed to sweep up its line of consumer products for $14.2 billion.

The deal means brands including Claritin, Dr. Scholl's and Coppertone will now join Bayer's consumer lineup which includes brands such as Aleve, Alka-Seltzer and One-a-Day vitamins.

The deal will make Bayer a leader in non-prescription consumer healthcare products, with a heavy presence in dermatology and gastrointestinal products. The company says it will also push Bayer into the number-two slot in the cold, allergy, sinus and flu category.

Merck has been talking about possibly selling or spinning off its consumer and animal health units for some time.

The companies also announced that they were going into business together as part of cardiovascular disease collaboration. The deal includes a $1-billion payment to Bayer, along with milestone payments.

The two will focus on soluble guanylate cyclase modulators and will include clinical development of Phase-II vericiguat and Adempas which is already approved for hypertension. Bayer and Merck will share development costs and profits, and will co-promote “in territories where they are not the lead.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...